Basic information on the 4D Molecular Therapeutics Share
Impact Score
Description 4D Molecular Therapeutics Share
4D Molecular Therapeutics Inc. is a biotechnology company focused on designing and developing gene therapies for severe genetic diseases, primarily targeting diseases in the ophthalmology, cardiology, and pulmonary spaces.4D Molecular Therapeutics Share Sustainability Performance
Climate
Society
Gender
The company is sustainable in this area.
The company is not yet sustainable in this area.
The company is not sustainable in this area.
No data available.
Renewable Energy
Greenhouse Gas Emissions
Supply Chain
Waste Recycling
Sustainable
Not yet sustainable
Not sustainable
No data
We measure the sustainability of companies based on 12 criteria. Learn more about our method.
Compare 4D Molecular Therapeutics with ...
4D Molecular Therapeutics
?
Impact Score
Climate
Society
Gender
Sources of sustainability performance
| Metric | Value | Unit | Year | PDF Name | PDF Page | |
|---|---|---|---|---|---|---|
CEO-to-Employee Pay Ratio | ||||||
| 227 | employees | 2024 | 0001140361-25-016323.pdf | 33 | ||
| David Kirn | 2024 | 0001140361-25-016323.pdf | 123 | |||
| 1 009 004 | ($) | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 30 | ||
| 57 383 | dollars in thousands): | 2024 | 0001140361-25-016323.pdf | 108 | ||
Harassment and Discrimination at the Workplace | ||||||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 3 | |||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 2 | |||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 2 | |||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 10 | |||
Union Formation and Collective Bargaining Power | ||||||
| 227 | employees | 2024 | 0001140361-25-016323.pdf | 33 | ||
| 0 | employees | 2024 | 0001140361-25-016323.pdf | 33 | ||
Women on the Board | ||||||
| 5 | Name | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 28 | ||
| 0 | Name | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 28 | ||
| 2 | Name | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 11 | ||
| 7 | members | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 19 | ||
Find more sustainable shares
© 2025 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The source of ETF data is the websites and data sheets of the respective ETF providers.Logos provided by Clearbit (https://clearbit.com/). All trademarks and logos appearing on this website are the property of their respective owners and are used here for informational and educational purposes only, under fair use guidelines. We claim no affiliation with, nor endorsement by, the companies whose trademarks and logos are displayed. This website is independent of the brands analyzed and receives no direct or indirect compensation from them.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support!